文献速递心脑血管急症

阿松德西安用于卒中二级预防

Asundexian for Secondary Stroke Prevention.
PubMed 文献 · N Engl J Med · 2026-01-01
一句话结论非心源性栓塞性缺血性卒中或高危TIA后72小时内,在抗血小板治疗基础上加用阿松德西安50 mg每日一次,较安慰剂降低缺血性卒中风险且不增加大出血。

OCEANIC-STROKE为3期双盲随机对照试验,纳入非心源性栓塞性缺血性卒中或高危TIA后72小时内、且具备非腔隙性梗死影像、动脉粥样硬化病史或脑血管影像动脉粥样硬化斑块至少一项的患者12,327例,随机接受阿松德西安50 mg每日一次或安慰剂,并联合计划的双联或单联抗血小板治疗。主要疗效终点缺血性卒中发生率阿松德西安组6.2% vs 安慰剂组8.4%(原因别风险比0.74,95%CI 0.65–0.84,P<0.001)。主要安全终点大出血两组相似(1.9% vs 1.7%;原因别风险比1.10,95%CI 0.85–1.44)。

要点

  • 非心源性栓塞性缺血性卒中或高危TIA后72小时内,阿松德西安50 mg每日一次联合抗血小板治疗,缺血性卒中6.2% vs 安慰剂8.4%(原因别HR 0.74,95%CI 0.65–0.84,P<0.001)。
  • 主要安全终点大出血阿松德西安组1.9% vs 安慰剂组1.7%(原因别HR 1.10,95%CI 0.85–1.44),两组相似。
  • 关键次要终点心血管原因死亡、心肌梗死或卒中复合终点阿松德西安组低于安慰剂组。
  • 不良事件发生率阿松德西安组69.3% vs 安慰剂组70.1%,严重不良事件19.2% vs 19.5%。
  • 适用人群需至少满足一项:影像学非腔隙性梗死、动脉粥样硬化病史、脑血管影像示任何部位动脉粥样硬化斑块。

适用人群与场景

  • 非心源性栓塞性缺血性卒中或高危TIA后72小时内随机化的患者。
  • 至少满足以下一项:影像学非腔隙性梗死、动脉粥样硬化病史、脑血管影像示任何部位动脉粥样硬化斑块。
  • 所有患者均计划接受双联或单联抗血小板治疗。

处置流程与药物剂量

  • 在计划的双联或单联抗血小板治疗基础上,加用阿松德西安50 mg每日一次口服,或安慰剂。
  • 随机化时间为非心源性栓塞性缺血性卒中或高危TIA症状发作后72小时内。

研究设计与关键结果

  • 3期双盲随机对照试验,12,327例患者随机分配至阿松德西安组(6162例)或安慰剂组(6165例)。
  • 主要疗效终点缺血性卒中发生率:阿松德西安组6.2% vs 安慰剂组8.4%,原因别风险比0.74(95%CI 0.65–0.84),P<0.001。
  • 关键次要终点心血管原因死亡、心肌梗死或卒中复合终点发生率阿松德西安组低于安慰剂组。
  • 主要安全终点大出血发生率:阿松德西安组1.9% vs 安慰剂组1.7%,原因别风险比1.10(95%CI 0.85–1.44),两组相似。
  • 不良事件发生率:阿松德西安组69.3% vs 安慰剂组70.1%;严重不良事件发生率:阿松德西安组19.2% vs 安慰剂组19.5%。

证据类型、等级与局限

  • 证据类型:3期双盲随机对照试验(OCEANIC-STROKE,NCT05686070),由拜耳资助。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于非心源性栓塞性缺血性卒中或高危TIA后72小时内、具备非腔隙性梗死影像、动脉粥样硬化病史或脑血管影像动脉粥样硬化斑块至少一项且接受抗血小板治疗的患者,加用阿松德西安50 mg每日一次可降低缺血性卒中风险,且不增加大出血风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients with noncardioembolic ischemic stroke or transient ischemic attack (TIA) are at risk for recurrent stroke. Low factor XI levels are associated with a reduced risk of ischemic stroke. Asundexian inhibits activated factor XI. Whether the addition of asundexian to antiplatelet therapy would be superior to antiplatelet therapy alone for the secondary prevention of ischemic stroke is unclear.

METHODS: In this phase 3, double-blind trial, we randomly assigned patients within 72 hours after the onset of a noncardioembolic ischemic stroke or high-risk TIA to receive asundexian (50 mg once daily) or placebo, in addition to planned dual or single antiplatelet therapy. Patients had at least one of the following: a nonlacunar infarct on imaging, a history of atherosclerosis, or evidence of atherosclerotic plaque at any location on cerebrovascular imaging. The primary efficacy outcome was ischemic stroke. The composite of death from cardiovascular causes, myocardial infarction, or stroke was a key secondary outcome. The primary safety outcome was major bleeding.

RESULTS: Among 12,327 patients who underwent randomization (6162 to the asundexian group and 6165 to the placebo group), the incidence of ischemic stroke was lower in the asundexian group than in the placebo group (6.2% vs. 8.4%; cause-specific hazard ratio, 0.74; 95% confidence interval [CI], 0.65 to 0.84; P<0.001). The incidence of the composite of death from cardiovascular causes, myocardial infarction, or stroke was lower in the asundexian group than in the placebo group. The incidence of major bleeding was similar in the asundexian group and the placebo group (1.9% and 1.7%, respectively; cause-specific hazard ratio, 1.10; 95% CI, 0.85 to 1.44). The incidence of adverse events was 69.3% in the asundexian group and 70.1% in the placebo group; the incidence of serious adverse events was 19.2% and 19.5%, respectively.

CONCLUSIONS: Among patients with noncardioembolic ischemic stroke or high-risk TIA treated with antiplatelet therapy, asundexian at a daily dose of 50 mg resulted in lower risks of ischemic stroke and major cardiovascular events than placebo, without a higher risk of major bleeding. (Funded by Bayer; OCEANIC-STROKE ClinicalTrials.gov number, NCT05686070.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Sharma M, Dong Q, Hirano T, et al. Asundexian for Secondary Stroke Prevention. N Engl J Med. 2026. PMID: 41985132. doi:10.1056/NEJMoa2513880

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。